LOS ANGELES — Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (Nasdaq:STML) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Stemline shares between January 19, 2017 and February 1, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 4, 2017 lead plaintiff deadline.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
On February 2, 2017, Bloomberg confirmed that a patient undergoing a clinical trial of Stemline’s cancer drug SL-401 died from a severe side effect, the third death related to SL-401 toxicity.
When this information was revealed to the public, the value of Stemline stock fell sharply, causing investors severe harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/